The PE Ratio as of November 2024 (TTM) for Immatics N.V. (IMTX) is -11.86

According to Immatics N.V.’s latest financial reports and current stock price. The company's current PE Ratio is -11.86. This represents a change of -55.57% compared to the average of -26.69 of the last 4 quarters.

Immatics N.V. (IMTX) Historical PE Ratio (quarterly & annually)

How has IMTX PE Ratio performed in the past?

The mean historical PE Ratio of Immatics N.V. over the last ten years is -6.41. The current -11.86 PE Ratio has changed 18.39% with respect to the historical average. Over the past ten years (40 quarters), IMTX's PE Ratio was at its highest in in the March 2022 quarter at 1.33. The PE Ratio was at its lowest in in the March 2024 quarter at -82.62.

Immatics N.V. (IMTX) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Immatics N.V. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Immatics N.V. (IMTX) Average PE Ratio

How has IMTX PE Ratio performed in the past?

The current PE Ratio of Immatics N.V. (IMTX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Immatics N.V. (IMTX) PE Ratio vs. Peers

How is IMTX’s PE Ratio compared to its peers?

Immatics N.V.’s PE Ratio is greater than Crinetics Pharmaceuticals, Inc. (-16.16), less than ALX Oncology Holdings Inc. (-0.49), less than BioAtla, Inc. (-0.93), less than Aerovate Therapeutics, Inc. (-0.91), less than Keros Therapeutics, Inc. (-11.12), less than Syndax Pharmaceuticals, Inc. (-4.63), less than Mineralys Therapeutics, Inc. (-4.06), less than Replimune Group, Inc. (-5.51), greater than Janux Therapeutics, Inc. (-45.40), greater than Fennec Pharmaceuticals Inc. (-120.74), greater than Edgewise Therapeutics, Inc. (-24.30), less than Harmony Biosciences Holdings, Inc. (15.80), less than Inhibrx Biosciences, Inc. (0), less than Merus N.V. (0.13), greater than Lyell Immunopharma, Inc. (-12.70), less than Kronos Bio, Inc. (-1.19), less than null (-0.64),

Build a custom stock screener for Immatics N.V. (IMTX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Immatics N.V. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Immatics N.V. (IMTX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Immatics N.V. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.